A Rare Skin Rash: Linezolid-Induced Purpuric Drug Eruption without Vasculitis in a Puerto Rican Man.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
05 Dec 2023
05 Dec 2023
Historique:
medline:
6
12
2023
pubmed:
5
12
2023
entrez:
5
12
2023
Statut:
epublish
Résumé
BACKGROUND Cutaneous adverse drug reactions are the skin's response to a systemic exposure to drugs. Linezolid is an oral oxazolidine used to treat methicillin-resistant Staphylococcus aureus infections. Even though it has well-known adverse effects, purpuric cutaneous adverse drug reactions to linezolid have been scarcely described. This report is of a Puerto Rican man in his 80s who developed an extensive purpuric drug eruption secondary to linezolid use. Clinicians should be aware of this phenomenon, since prompt identification and discontinuation of the agent are essential for recovery. CASE REPORT An 89-year-old Puerto Rican man was given oral linezolid therapy for healthcare-associated pneumonia and developed a widespread, purpuric cutaneous eruption 5 days into therapy. His condition prompted immediate discontinuation of the drug. Forty-eight hours after stopping the medication, he visited the Emergency Department. Abdominal punch biopsy revealed a superficial and perivascular lymphocytic infiltrate with dermal eosinophils, a pathologic finding consistent with a purpuric drug eruption. This allowed for a timely diagnosis, exclusion of other mimickers, such as cutaneous vasculitis, and effective management. CONCLUSIONS Cutaneous adverse drug reactions to linezolid have been scarcely reported in the literature. Due to the low incidence of this manifestation, the identification of the causative agent and accompanying treatment may be delayed. Mainstays in therapy are avoidance of the offending agent and treatment with corticosteroids, antihistamines, barrier ointments, and oral analgesics. Primary healthcare providers should be aware of linezolid-induced cutaneous manifestations, diagnostic clues, and treatment options so they can rapidly identify and effectively treat such complications.
Identifiants
pubmed: 38050348
pii: 941725
doi: 10.12659/AJCR.941725
pmc: PMC10711635
doi:
Substances chimiques
Linezolid
ISQ9I6J12J
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e941725Références
Ann Pharmacother. 2018 Dec;52(12):1263-1264
pubmed: 30066575
J Antimicrob Chemother. 2003 May;51 Suppl 2:ii45-53
pubmed: 12730142
Med Clin (Barc). 2005 Apr 30;124(16):639
pubmed: 15871789
Am J Kidney Dis. 2009 Dec;54(6):e17-20
pubmed: 19733945
J Cutan Pathol. 2009 Jul;36(7):793-5
pubmed: 19519611
Clin Infect Dis. 2003 Jan 15;36(2):159-68
pubmed: 12522747
Dermatopathology (Basel). 2022 Mar 30;9(2):111-121
pubmed: 35466243
Antimicrob Agents Chemother. 2006 Apr;50(4):1599-602
pubmed: 16569895
Clin Rev Allergy Immunol. 2022 Jun;62(3):463-475
pubmed: 34910281
An Bras Dermatol. 2020 Jul - Aug;95(4):493-507
pubmed: 32527591
Aust Prescr. 2022 Apr;45(2):43-48
pubmed: 35592375